Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGAV | P06756 | 2/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325205 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGB5ITGB6LMNA | |
| SCHEMBL6321357 | 0.77 | ITGB3 (0.42) | ITGB3ITGAVITGB5ITGB6TP53 | |
| SCHEMBL27144535 | 0.70 | MEN1 (0.51) | TP53TSHRRAB9APLA2G4BMEN1 | |
| SCHEMBL5429541 | 0.70 | PLA2G4B (0.68) | TP53TSHRPLA2G4BLMNAALDH1A1 | |
| SCHEMBL29089242 | 0.70 | PLA2G4B (0.68) | TP53TSHRPLA2G4BLMNA | |
| Bicarbonate SCHEMBL6207665 | 0.70 | RAB9A (0.66) | TP53TSHRRAB9APLA2G4BMEN1 | |
| SCHEMBL6847318 | 0.70 | PPARG (0.57) | TP53TSHRRAB9APLA2G4BNPC1 | |
| Propionic Acid SCHEMBL27556614 | 0.69 | LTA4H (0.69) | TP53TSHRPLA2G4B | |
| SCHEMBL8744429 | 0.67 | PLA2G4B (0.73) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL1285778 | 0.67 | PLA2G4B (0.77) | TP53TSHRPLA2G4BLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6841449-B1 | Two-step process for nickel deposition | ADVANCED MICRO DEVICES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6689687-B1 | Two-step process for nickel deposition | ADVANCED MICRO DEVICES, INC. | 2004-02-10 | — | — | US | disclosed |
| US-6632740-B1 | Two-step process for nickel deposition | ADVANCED MICRO DEVICES, INC. | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885ITGB5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.